For the study, researchers assessed Tideglusib’s ability to prompt stem cell activation in the damaged teeth of mice. They inserted biodegradable collagen sponges, soaked in Tideglusib, into the mice’s cavities and sealed them for several weeks.
Researchers discovered the drug successfully activated stem cells inside the mice teeth, causing damaged areas to regenerate the hard dentin material that makes up the majority of a tooth, according to the report.
“The simplicity of our approach makes it ideal as a clinical dental product for the natural treatment of large cavities, by providing both pulp protection and restoring dentin,” said lead author Paul Sharpe, PhD, professor and researcher at King’s College London, according to Science Alert. “In addition, using a drug that has already been tested in clinical trials for Alzheimer’s disease provides a real opportunity to get this dental treatment quickly into clinics.”
Researchers plan to next study the process in rats, before potentially moving to clinical trials.
More articles on supply chain:
Naloxone now available free-of-charge for at-risk youth in Oklahoma
St. Jude Medical releases cybersecurity updates for vulnerable heart devices
Egalet earns FDA approval for abuse-deterrent opioid painkiller
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
